Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx (NYSE AMERICAN: VNRX) reported second quarter 2026 revenue of approximately $0.4 million, roughly in line with Q2 2025, and first-half 2026 revenue of $1.4 million, representing 112% growth over the first half of 2025.
Operating expenses in Q2 2026 were 32% lower year over year, contributing to an operating loss of $4.2 million, down 34% versus Q2 2025. Net cash used in operating activities was $5.2 million, 18% lower than the prior-year quarter. Receipts included $1.2 million from at-the-market equity sales and $4.1 million from a confidentially marketed public offering.
Volition highlighted ongoing licensing discussions with more than a dozen diagnostic and liquid biopsy companies, a collaboration with Sysmex, a Nu.Q Vet feline lymphoma manuscript linked to a potential $5 million milestone, progress toward reimbursement for Nu.Q Lung Cancer, and its first peer-reviewed Capture-Seq liquid biopsy paper. The company estimates its total addressable markets at over $27 billion annually.
Volition (NYSE American: VNRX) reported that its Nu.Q® NETs lateral flow finger-prick prototype showed high correlation with its CE-marked automated Nu.Q® NETs laboratory assay in critically ill sepsis patients, supporting use outside centralized labs in the $3.8 billion global NETosis testing market.
According to Volition, H3.1 nucleosome levels measured from finger-prick samples on a lateral flow device tracked closely with plasma results from the lab assay, with a Spearman correlation of 0.85 and Pearson correlation of 0.881. The study, part of the SUMMIT program, used capillary and plasma samples from Intensive Care patients and indicated feasibility of rapid, point-of-care immune disruption detection, including in sepsis, across settings such as ER, ICU, doctors’ offices, or potentially at home. Volition highlighted 166 million estimated global sepsis cases and 31.5% of global deaths in 2021 linked to sepsis, and said decentralized testing could expand its addressable market, including via NGO and strategic partnerships in low-income countries.
VolitionRx (NYSE American: VNRX) has scheduled its Second Quarter 2026 Earnings and Business Update conference call for Friday, August 14, 2026 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. Central European Time). The call will cover financial and operating results, important Q2 events, subsequent developments, and upcoming milestones.
The call will be hosted by Group Chief Marketing & Communications Officer Louise Batchelor, President and Group CEO Cameron Reynolds, and Group CFO Terig Hughes. Investors can join via regional dial-in numbers using Conference ID 13762190, or access a live audio webcast and replay available until August 28, 2026.
Volition (NYSE AMERICAN: VNRX) announced publication of the first peer‑reviewed paper detailing its new Capture‑Seq™ liquid biopsy technology, which isolates and analyzes >99% pure circulating tumor-derived DNA (ctDNA) from blood plasma by targeting CTCF-bound DNA.
According to Volition, the method combines physical enrichment and bioinformatic filtering to remove virtually all non-tumor cfDNA, generating highly enriched cancer-associated sequence datasets. Early studies reported no false positives and detection of 49/49 cancers in an initial cohort, 13/14 later-stage cancers in a second cohort, and, in a subsequent 81-subject blinded validation, 95% detection of stage I/II colorectal and lung cancers. The company is fast-tracking development, has filed new patents, estimates a total addressable market of approximately $23 billion for multi-cancer early detection and over $13 billion for minimal residual disease, and is in active discussions and technical evaluations with major liquid biopsy and diagnostic companies.
Volition (NYSE AMERICAN: VNRX) reported new clinical and scientific evidence supporting its Nu.Q® NETs platform, focused on the Nu.Q® H3.1 assay as a sepsis biomarker within an estimated $3.8 billion annual total addressable market. Management said it is in active discussions with several large diagnostic companies to accelerate Nu.Q® NETs development.
According to Volition and collaborating clinicians, Nu.Q® H3.1 has shown the ability to distinguish sepsis from non-infectious systemic inflammation, correlate with disease severity, and provide prognostic information on outcomes such as organ failure and mortality. The company highlighted that most supporting papers on its Nu.Q® NETs assay in NETosis-related diseases have now been peer reviewed and published.
Volition (NYSE AMERICAN: VNRX) reported new clinical data on its Nu.Q® Cancer Assay in newly diagnosed non-small cell lung cancer. The study suggests prognostic value for overall and progression-free survival, and may help identify patients suitable for curative care. The paper is under peer review.
Clinical certification at Hospices Civils de Lyon is completed, and a reimbursement dossier is being prepared under France’s RIHN framework. Volition is in discussions with hospital networks and potential licensees and anticipates about €50 revenue per test in a direct sales model.
VolitionRx (NYSE American: VNRX) announced a collaboration with Sysmex (TYO: 6869) to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The partnership supports Volition's strategy to out-license its NETs test globally and target diseases associated with NETosis, including sepsis.
According to Volition, the Nu.Q NETs test aims to aid clinical decision-making, support personalized care, and offer low-cost monitoring of patient condition. The company cites a $3.8 billion Total Addressable Market for the Nu.Q NETs assay.
VolitionRx (NYSE American: VNRX) priced a public offering of 2,960,000 common shares plus warrants for up to 1,480,000 shares at a combined price of $1.55 per share and half warrant, for expected gross proceeds of about $4.6 million before fees.
Warrants are immediately exercisable at $1.55 per share for five years and could add about $2.3 million in gross proceeds if fully exercised. The offering, placed by Maxim Group, is expected to close on June 9, 2026, subject to customary conditions.
Volition (NYSE AMERICAN: VNRX) filed a new patent application to protect use of its Nu.Q® NETs test for triaging and monitoring patients suspected of Ebola infection.
The CE-Marked automated assay and a finger-prick LFT prototype target frontline use in outbreak zones, with Volition actively seeking global strategic partners.
Volition (NYSE AMERICAN: VNRX) reported strong commercial and clinical progress across multi-billion-dollar markets. Q1 2026 revenue reached $1 million, a 300% year-over-year increase, supported by momentum in cancer detection, companion animal health, and sepsis/NETosis applications.
Highlights include a Capture-Seq™ cancer manuscript with >95% sensitivity and 95% specificity in early-stage cancers, a Nu.Q® Vet feline lymphoma study expected to unlock a $5 million milestone upon publication, inclusion of Nu.Q® NETs in the $7.3 million DETECSEPS sepsis program, and progress toward French reimbursement for lung cancer testing. Volition cites annualized TAMs of $23B for Capture-Seq™ cancer detection, $3.8B for Nu.Q® NETs, and $1.0B+ for Nu.Q® Vet canine/feline.